Hyperimmune plasma (HIP) at 10 mL/kg i/v administered to dogs with canine parvovirus (CPV) within the first 6 hours of hospitalisation improves markers for shock during the initial 24 hours of hospitalisation but no effects were observed on duration of hospitalisation or mortality
Journal citation

Acciacca, R.A., Sullivan, L.A., Webb, T.L., et al (2020)
Clinical evaluation of hyperimmune plasma for treatment of dogs with naturally occurring parvoviral enteritis
Journal of Veterinary Emergency and Critical Care30 (5) 525– 533

Published  September/October 2020

Type of study
  • Prospective, randomised, placebo-controlled clinical trial
  • n = 31 dogs
Key points
  • This is the first randomised, placebo-controlled study aimed at determining the clinical efficacy of a commercially available HIP product in dogs with CPV
  • A commercially available product containing antibodies to CPV and lipopolysaccharide (LPS) endotoxin was used
  • Dogs treated with HIP demonstrated a lower value than the placebo group for both shock index and plasma lactate concentration, suggesting that HIP treatment was associated with improved cardiovascular stability and perfusion by 24 hours after hospitalisation
  • 77% of dogs treated with HIP went on to develop neutropenia compared to 33% of placebo-treated dogs, though this difference was not statistically significant
  • HIP was well tolerated in this population of dogs
  • Overall treatment success, defined as survival to hospital discharge, was 16 of 16 (100%) for the HIP group and 14 of 15 (93.3%) for the placebo group


  • Small number of dogs
  • Neither the timing nor the dose of HIP was standardised to the development of clinical signs or other potential cytokine or LPS measures but rather to the time of hospital presentation or the dog’s body weight, respectively
  • CPV or LPS antibody titres within the HIP product were not quantified during the current study
  • HIP was safely provided to dogs with CPV with no noted adverse effects in this population of dogs
  • Future studies evaluating dose and timing of HIP administration are needed to better define the possible clinical benefits of this product